Pfizer (PFE) Current Deferred Revenue (2020 - 2025)
Pfizer (PFE) posted quarterly Current Deferred Revenue of $784.0 million for Q4 2025, down 48.11% year-over-year from $1.5 billion in Q4 2024, and down 15.15% quarter-over-quarter from $924.0 million in Q3 2025.
Pfizer (PFE) Current Deferred Revenue (2020 - 2025) Analysis & Trends
Pfizer (PFE) has reported Current Deferred Revenue for 6 consecutive years, with $784.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Deferred Revenue fell 48.11% year-over-year to $784.0 million; the TTM figure through Dec 2025 stood at $784.0 million (down 48.11% YoY), while the FY2025 annual figure was $784.0 million, down 48.11% from the prior year.
- Current Deferred Revenue eased to $784.0 million in Q4 2025 per PFE's latest filing, from $924.0 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $4.3 billion in Q3 2021 and bottomed at $784.0 million in Q4 2025.
- Historically, Current Deferred Revenue has averaged $2.3 billion across 5 years, with a median of $2.3 billion in 2021.
- Annual changes were most pronounced in 2021 — Current Deferred Revenue surged 175.56% — and 2023, when it tumbled 66.19%.
- Pfizer's Current Deferred Revenue stood at $3.1 billion in 2021, then slipped by 17.84% to $2.5 billion in 2022, then increased by 7.14% to $2.7 billion in 2023, then plunged by 44.04% to $1.5 billion in 2024, then slumped by 48.11% to $784.0 million in 2025.
- Business Quant data shows PFE's Current Deferred Revenue at $784.0 million in Q4 2025, $924.0 million in Q3 2025, and $1.1 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.18 Bn | 632.42 Bn | 17.26 Bn |
| 2 | AbbVie | 470.31 Bn | 463.74 Bn | 12.70 Bn |
| 3 | Merck | 377.76 Bn | 370.62 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.30 Bn | 295.61 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.84 Bn | 252.94 Bn | 12.86 Bn |
| 6 | Amgen | 236.85 Bn | 222.86 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 182.10 Bn | 178.92 Bn | 6.22 Bn |
| 8 | Pfizer | 159.40 Bn | 147.70 Bn | 10.94 Bn |
| 9 | Gsk | 106.36 Bn | 102.19 Bn | 8.24 Bn |
| 10 | Sanofi | 54.99 Bn | 47.61 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 784.00 Mn |
| Sep 28, 2025 | 924.00 Mn |
| Jun 29, 2025 | 1.12 Bn |
| Mar 30, 2025 | 1.01 Bn |
| Dec 31, 2024 | 1.51 Bn |
| Sep 29, 2024 | 2.02 Bn |
| Jun 30, 2024 | 2.53 Bn |
| Mar 31, 2024 | 2.50 Bn |
| Dec 31, 2023 | 2.70 Bn |
| Jul 2, 2023 | 1.29 Bn |
| Apr 2, 2023 | 1.75 Bn |
| Dec 31, 2022 | 2.52 Bn |
| Jul 3, 2022 | 3.80 Bn |
| Apr 3, 2022 | 3.11 Bn |
| Dec 31, 2021 | 3.07 Bn |
| Oct 3, 2021 | 3.53 Bn |
| Jul 4, 2021 | 4.29 Bn |
| Apr 4, 2021 | 2.05 Bn |
| Dec 31, 2020 | 1.11 Bn |